Washington University/ Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

• 批准号: 8605719
• 负责人: NANCY L BARTLETT
• 金额: $ 154.84万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-02 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8605719
• 关键词: American College of Radiology Imaging Network; American College of Surgeons Oncology Group; Area; Cancer Center; Cancer and Leukemia Group B; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Commit; Communication; Comprehensive Cancer Center; Conduct Clinical Trials; Correlative Study; Development; Diagnostic; Diagnostic Neoplasm Staging; Disorder by Site; Eastern Cooperative Oncology Group; Enrollment; Environment; Fostering; Goals; Gynecologic Oncology; Gynecologic Oncology Group; Illinois; Image; Institution; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Medical Oncology; Mentors; Mentorship; Mission; Missouri; Modality; Patients; Physicians; Play; Principal Investigator; Prognostic Marker; Radiation Oncology; Radiation Therapy Oncology Group; Radiology Specialty; Recording of previous events; Research; Research Personnel; Site; Specialist; Therapy Clinical Trials; Thoracic Oncology; Translational Research; Universities; Washington; Work; anticancer research; biobank; cancer therapy; design; experience; improved; leukemia/lymphoma; malignant breast neoplasm; member; metropolitan; oncology; operation; professor; programs; public health relevance; tool

DESCRIPTION (provided by applicant): The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) Lead Academic Site is to create a supportive environment that will foster 1) scientific leadership and mentorship, 2) development of cooperative group clinical trials, 3) substantial accrual to clinical trials across the entire NCTN and 4) exceptional conduct of clinical trials. Investigators at WU/SCC are committed to work to enhance the research goals of the NCTN Program and to enroll patients to NCTN trials across the Network. WU/SCC investigators have a long history of enthusiastic participation in the cooperative groups including ACOSOG, ACRIN, CALGB, GOG, and RTOG and will continue to play key roles in the newly merged groups including the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 U10 Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Bryan F. Meyers, MD, MPH (Professor, Thoracic Oncology), Jeff M. Michalski, MD, MBA (Professor, Radiation Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology) and Barry A. Siegel, MD (Professor, Radiology). All members of the senior leadership team have extensive clinical trial experience, including many years of cooperative group involvement, and are committed to providing guidance for an institution-wide cooperative group NCTN UI0. WU/SCC is consistently among the top accruing institutions in each of the cooperative groups with outstanding accrual across many disease sites. Between January 2007 and June 2012, WU/SCC accrued 1633 patients to cooperative group therapeutic trials, an average of 297 patients per year for the last 5.5 years (171 ACOSOG, 1024 CALGB/Alliance, 156 GOG, and 282 RTOG). During this same interval, 727 patients had biospecimens collected and 101 patients were accrued to advanced imaging studies through ACRIN. WU/SCC investigators are highly motivated to contribute to the scientific mission of the NCTN, particularly in the areas of breast cancer, gynecological oncology, thoracic oncology, Gl oncology, GU oncology, leukemia, and lymphoma. Strong translational science in breast cancer, lung cancer, and AML at WU/SCC, along with large institutional biorepositories, will provide many opportunities for unique contributions to correlative studies associated with cooperative group therapeutic trials. This institution-wide UIO will facilitate enhanced communication and collaboration among disease site and modality specialists and improve our potential for contributions to the NCTN operation.

描述（由申请人提供）：拟议的华盛顿大学/现场癌症中心（WU/SCC）的主要目标是创造一个支持性环境，将促进培养1）科学领导力和指导，2）开发合作集团临床试验，3）3）在整个NCTN中进行实质性的临床试验 4）临床试验的特殊行为。 WU/SCC的研究人员致力于提高NCTN计划的研究目标，并将患者纳入整个网络的NCTN试验。 WU/SCC调查人员在包括Acosog，Acsog，Acrin，Calgb，GOG和RTOG在内的合作团体中有着悠久的历史，并且将继续在新合并的小组中扮演关键角色，包括肿瘤学临床试验联盟，ECOG-ACRAIN CACRIN CACRIN CARPAN RESERCE GROUP和NRG肿瘤学。 WU/SCC将有5名U10主要研究人员组成的高级领导团队，包括Nancy L. Bartlett，医学博士（医学肿瘤学教授），Bryan F. Meyers，MD，MPH，MPH（胸腔肿瘤学教授），Jeff M. Michalski，M。M. M. Michalski，M. A. Siegel，医学博士（放射学教授）。高级领导团队的所有成员都有丰富的临床试验经验，包括多年的合作小组参与，并致力于为整个机构合作集团NCTN UI0提供指导。 WU/SCC始终是在许多疾病部位都有出色应计的每个合作团体中最高的机构之一。在2007年1月至2012年6月之间，WU/SCC累积了1633名患者进行合作组治疗试验，在过去的5.5年中，每年平均有297名患者（171 AcoSOG，1024 CALGB/Alliance，156 GOG和282 RTOG）。在同一时间间隔内，有727名患者收集了生物测量，并通过ACRIN进行了101例患者进行高级成像研究。 WU/SCC的研究人员高度动力为NCTN的科学任务做出了贡献，特别是在乳腺癌，妇科肿瘤学，胸腔肿瘤学，GL肿瘤学，GU肿瘤学，白血病和淋巴瘤领域。 WU/SCC的乳腺癌，肺癌和AML的强大转化科学以及大型的机构生物疗法将为与合作群体治疗试验相关的相关研究提供许多独特的贡献机会。该机构范围内的UIO将促进疾病现场和模式专家之间的沟通和协作，并提高我们对NCTN运营的贡献的潜力。